Investor Presentaiton

12 Advanz Partnership/BD Update 1 Expands partnership with Advanz Pharma to include 5 additional biosimilar candidates including proposed biosimilars to Simponi (golimumab) and Entyvio (vedolizumab) and 3 early-stage, undisclosed biosimilars 2 Up-front payment of $60 million 3 Additional payments of up to ~$280 million based on achievement of certain development and commercial milestones in addition to the customary revenue share of ~40% 4 Demonstrates the ability of a business-to-business (B2B) platform to monetize early-stage assets 5 Alvotech's Business Development (BD) pipeline remains active; Key activities going forward focus on oncology and oncology related assets with AVTO3 and AVT33 with rights available in U.S. and Europe alvotech O ALVOTECH. ALL RIGHTS RESERVED

View entire presentation